New launch of Mounjaro® 2.5 mg / 5 mg Ateos®, the world’s first sustained release GIP/GLP-1 receptor agonist

Mitsubishi Tanabe Pharma Corporation, a member of the Mitsubishi Chemical Group, has announced the following press release.

■Mitsubishi Tanabe Pharma　Press Release
New launch of Mounjaro® 2.5 mg / 5 mg Ateos®, the world’s first sustained release GIP/GLP-1 receptor agonist 
https://www.mt-pharma.co.jp/e/news/assets/pdf/e_MTPC230418.pdf